Literature DB >> 19541516

Recurrence risk after withdrawal of antiepileptic drugs in children with epilepsy: a prospective study.

J Ramos-Lizana1, J Aguirre-Rodríguez, P Aguilera-López, E Cassinello-García.   

Abstract

AIM: To study recurrence risk after withdrawal of antiepileptic drugs in children with epilepsy.
METHODS: All children younger than 14 with two or more unprovoked seizures 24h apart who were seen at our Hospital between 1994 and 2004 were included consecutively and prospectively followed. Patients previously examined in other centres were excluded. All patients who entered a remission were proposed to stop medication and were followed.
RESULTS: Three hundred and fifty three children with two or more unprovoked seizures were attended. A total of 238 entered a remission period and were proposed to stop medication, 216 accept. Mean seizure-free time before medication withdrawal was 2.2 years. Kaplan-Meier estimate of recurrence risk was 23% at 2 years (95% CI: 17-29) and 28% at 5 years (95% CI: 22-34). A remote symptomatic etiology, various seizure types and a history of prior febrile seizures or prior neonatal seizures were associated with a significant increase in recurrence risk in univariable and multivariable analyses using Cox proportional hazards model. Recurrence risk at 2 years was 17% (95% CI: 11-23) for idiopathic/cryptogenic epilepsies and 41% (85% CI: 28-54) for remote symptomatic epilepsies. Recurrence risks at 2 years by epileptic syndrome were West syndrome (0%), benign rolandic epilepsy (10%), epilepsy without unequivocal partial or generalized seizures (11%), benign infantile seizures (13%), absence epilepsy (16%), cryptogenic partial epilepsies (20%), symptomatic partial epilepsies (45%), symptomatic generalized epilepsies (54%).
CONCLUSIONS: Recurrence risk after withdrawal of antiepileptic treatment in children is low. Etiology and syndromic diagnosis are the main predictive factors. 2009 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19541516     DOI: 10.1016/j.ejpn.2009.05.006

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  7 in total

1.  Stopping antiepileptic drugs: when and why?

Authors:  John D Hixson
Journal:  Curr Treat Options Neurol       Date:  2010-06-26       Impact factor: 3.598

2.  Risk of recurrence after discontinuation of antiepileptic drug therapy in children with epilepsy.

Authors:  Faruk Incecik; Ozlem M Herguner; Sakir Altunbasak; Gulen Mert; Nurcihan Kiris
Journal:  J Pediatr Neurosci       Date:  2014-05

Review 3.  Propofol-induced refractory status epilepticus at remission age in benign epilepsy with centrotemporal spikes: A case report and literature review.

Authors:  Lu Lu; Weixi Xiong; Yingying Zhang; Yingfeng Xiao; Dong Zhou
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

4.  Antiepileptic-drug tapering and seizure recurrence: Correlation with serum drug levels and biomarkers in persons with epilepsy.

Authors:  Sudhir C Sarangi; Sachin Kumar; Manjari Tripathi; Thomas Kaleekal; Surender Singh; Yogendra K Gupta
Journal:  Indian J Pharmacol       Date:  2022 Jan-Feb       Impact factor: 2.833

5.  Abnormal electroencephalogram (EEG) after drug withdrawal is a risk factor for epilepsy recurrence in children: a systematic review and meta-analysis.

Authors:  Shanwen Huang; Ruipeng Chen; Hao Chen; Gang Si
Journal:  Transl Pediatr       Date:  2022-06

6.  Risk factors for seizure reoccurrence after withdrawal from antiepileptic drugs in individuals who have been seizure-free for over 2 years.

Authors:  XingHua Tang; Peimin Yu; Ding Ding; Yan Ge; Yunbo Shi; Ping Wang; Guoxing Zhu; Zhen Hong
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

7.  Non-Invasive Brain Stimulation in Children With Unilateral Cerebral Palsy: A Protocol and Risk Mitigation Guide.

Authors:  Bernadette T Gillick; Andrew M Gordon; Tim Feyma; Linda E Krach; Jason Carmel; Tonya L Rich; Yannick Bleyenheuft; Kathleen Friel
Journal:  Front Pediatr       Date:  2018-03-16       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.